Journal of Cancer Research and Therapeutics

LETTER TO THE EDITOR
Year
: 2019  |  Volume : 15  |  Issue : 8  |  Page : 177-

Screening for prostate cancer starting at age 50–54 years


Beuy Joob1, Viroj Wiwanitkit2,  
1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Biological Science, Joseph Ayo Babalola University, Ilara-Mokin, Nigeria

Correspondence Address:
Dr. Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand




How to cite this article:
Joob B, Wiwanitkit V. Screening for prostate cancer starting at age 50–54 years.J Can Res Ther 2019;15:177-177


How to cite this URL:
Joob B, Wiwanitkit V. Screening for prostate cancer starting at age 50–54 years. J Can Res Ther [serial online] 2019 [cited 2021 Oct 24 ];15:177-177
Available from: https://www.cancerjournal.net/text.asp?2019/15/8/177/244229


Full Text



Sir,

The use of prostate-specific antigen (PSA) for screening of cancer is accepted for its usefulness. However, the interesting issue is the starting age. The recent report on “Screening for Prostate Cancer Starting at Age 50–54 Years” is very interesting.[1] This age is not too young and can save the cost in case of mass screening. Carlsson et al. concluded that “PSA screening for prostate cancer can decrease prostate cancer mortality among men aged 50–54 years.”[1] In fact, any screening program has to be validated for utility and cost-effectiveness in each setting. For PSA screening, the cost might be the obstacle for using as mass screening in some developing countries. In addition, the diagnostic ability and quality control of the test is the big issue to be discussed. Only a small error such as poor blood collection can result in aberrant PSA result.[2] In a report from Thailand, not only the cost but also the diagnostic property of the PSA is the big challenges in implementing PSA for mass screening of prostate cancer.[3] In addition, the cutoff value of PSA can be different in difference age groups and ethnics.[4] Finally, the exact usefulness of the PSA has to be concordant with good management of the positive case. Recently, Roth et al. noted that “for PSA screening to be cost-effective, it needs to be used conservatively and ideally in combination with a conservative management approach for low-risk disease.”[5]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, et al. Screening for prostate cancer starting at age 50-54 years. A population-based cohort study. Eur Urol 2017;71:46-52.
2Wiwanitkit V. Effect of thrombin tube on PSA determination, a clue for false negative in screening for prostate cancer. J Thromb Thrombolysis 2009;27:223-6.
3Wiwanitkit V. Prostate specific antigen for screening for prostate cancer: An appraisal of Thai reports. Asian Pac J Cancer Prev 2004;5:406-8.
4Gupta A, Gupta D, Raizada A, Gupta NP, Yadav R, Vinayak K, et al. Ahospital based study on reference range of serum prostate specific antigen levels. Indian J Med Res 2014;140:507-12.
5Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol 2016;2:890-8.